Paying a growth multiple (33× / 3.1× levered) for a mid-single-digit-growth business
One-line thesis. WM is a genuinely elite, recession-proof toll road on North American waste — 29% EBITDA margins, 29% ROE, wide moat, low beta — but at 33× trailing earnings and 3.1× net-debt/EBITDA the price already reflects the quality, leaving a ~5% revenue / ~12% EPS grower with little valuation cushion and no Synthos expert conviction behind it. Watch, own on a pullback.
◆ Synthos call — HoldWM is a solid business largely reflected at ~$235 — fine to keep, no reason to chase; it gets interesting again below ~$200.
Downside Risk (lower = safer)
5/10 · Moderate
Low beta 0.46 & recession-proof cash flows, but 33× trailing, 3.1× net-debt/EBITDA and priced at/above Street.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 21%/yrTo justify today’s $230, earnings would have to compound roughly 21% a year for 10 years (9% discount rate). Analysts forecast ~10%/yr, so the market is pricing in MORE than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
Waste Management is the biggest garbage and recycling company in North America. Every home, store, and factory needs its trash hauled away and buried in a landfill — and WM owns more landfills than anyone else. That makes it a boring but incredibly reliable business: people make garbage in good times and bad, so the money keeps coming in even in a recession.
The catch: everyone already knows it's a great business, so the stock is expensive. You're paying about $33 for every $1 the company earns — a rich price for a company whose sales only grow about 5% a year. Our verdict is Watch: a wonderful company, but not at a wonderful price. It would become a "buy" if the price dropped or the earnings caught up.
Here's what our three scores mean in everyday terms:
Downside Risk 5/10 (middle of the road). The business itself is very safe and the stock barely bounces around — but the high price and a big pile of debt mean a stumble would hurt.
Growth Quality 5/10 (solid but not exciting). Steady, very profitable, and durable — but it grows slowly, like a utility.
Exponential Potential 2/10 (low). It's already huge and growing slowly. Don't expect it to double quickly — this is a slow-and-steady compounder, not a rocket.
The one big worry: you are paying a premium price for a company that grows slowly, so the stock could go nowhere for a while if the market decides the price got ahead of itself.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLI (sector)), set to 100 a year ago
Solid = WM · dashed = S&P 500 · dotted = XLI (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$230.40
Market cap$93B
P/E trailing10×
P/E FY26E / FY27E28× / 25×
EV / Sales4.5×
EV / EBITDA15.6×
Gross margin32.1%
Net margin11.0%
Dividend yield1.54%
Beta0.457
52-wk range$197 – $247
RSI(14)68
50 / 200-DMA$221 / $221
12-mo return+1% (SPY +21%)
Street target$258 ($250–$264)
Analyst grades19 Buy · 16 Hold · 0 Sell
FMP ratingB
Next earnings2026-08-05
What the experts actually said 0 traceable claims on WM · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
Waste Management, Inc. (NYSE: WM) is North America's largest integrated environmental-services company: collection, transfer, recycling, and — critically — disposal. Its competitive heart is the largest network of solid-waste landfills on the continent (255 solid-waste landfills, plus hazardous-waste sites, ~96 material-recovery facilities and ~340 transfer stations as last disclosed), which are effectively impossible to permit and replicate today. Headquartered in Houston, ~61,700 employees, incorporated 1987 (as USA Waste Services), rebranded Waste Management 1998. Fiscal year ends December 31. CEO: James C. Fish Jr.
The business has two growth overlays on the core hauling-and-burying franchise: (a) sustainability — renewable natural gas (RNG) from landfill gas and recycling automation; and (b) the 2024 Stericycle acquisition (~$7.5B), which created the Healthcare Solutions (regulated medical-waste) segment and is the single biggest reason FY25 revenue jumped ~14%.
By geography: overwhelmingly United States (FY24 US ~$21.1B vs Canada ~$0.85B) — a North-America-only, US-concentrated footprint. That is a regulatory/pricing-power strength and limits FX risk, but caps geographic expansion runway.
Note the segmentation change: the FY24→FY25 "Landfill" and "Transfer" jumps and the new Healthcare Solutions line reflect reclassification plus the Stericycle integration, not organic surges — read segment deltas with that caveat.
2. The expert thesis — (none in the Synthos KB)
There is no expert coverage of WM in the Synthos knowledge base: total_claims = 0, zero net-bullish voices, zero cautionary voices. This is not a signal against the stock — waste services simply is not a sector our tracked expert panel (heavily tilted to tech, AI, biotech, and macro voices) discusses. It does mean the honest disclosure is explicit: every judgment in this note is fundamentals- and quant-driven, with no traceable claim_id conviction behind it. We do not manufacture conviction we do not have.
Where a conviction-track name (see our Eli Lilly note) can lean on a dozen reconciled expert voices, WM leans only on: its reported financials, live analyst consensus estimates (FMP), the Street's own ratings (19 Buy / 16 Hold / 0 Sell), and management's self-interested guidance (half-weighted, §9). Size the call accordingly.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
5 · Moderate
Beta 0.46 and utility-grade, recession-proof cash flows are genuinely defensive — but 33× trailing EPS, 3.1× net-debt/EBITDA, and a price sitting at/above the Street's own targets remove the valuation cushion. Cheap business, not-cheap stock.
Growth Quality
5 · Solid
29% EBITDA margin, 29% ROE, 9% ROIC, a near-impregnable landfill moat and pricing power (core price +6.3% in Q1'26) — but only ~5% forward revenue CAGR and ~12% EPS CAGR. High quality, low velocity.
Exponential Potential
2 · Low
A mature ~$92B compounder growing mid-single-digits and decelerating; the North-American waste TAM is largely already served. Near-zero probability of a multibagger from here.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them.
Case
Key assumptions
Fair value
Bull
Stericycle synergies + RNG/recycling growth projects drive margin above plan; FY27E EPS beats to ~$9.75 (vs $9.21 cons); market keeps paying a premium ~29× for the quality/defensiveness.
~$285 (+24%)
Base(our anchor)
Estimates roughly hit — FY27E EPS ~$9.21; a steady mid-single-digit grower with a wide moat earns a ~25× forward multiple, in line with its own history.
~$235 (+2%)
Bear
Recycling-commodity and RNG-credit prices stay soft, volume stays negative, integration costs linger; FY27E EPS misses to ~$8.50 and the multiple de-rates toward the market at ~22× as growth disappoints at a full price.
~$185 (−20%)
Synthos fair value = the base case, ~$235 (+2%), with the full $185–$285 span as the honest range. Our base sits below the Street's $258.50 consensus: we are not willing to underwrite a 28×+ forward multiple on a ~5% top-line grower, so we anchor to ~25× FY27E. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). WM is a high-quality compounder with essentially no exponential character:
Forward growth: revenue CAGR FY25→FY30E ~5.2% ($25.2B → $32.55B est); EPS CAGR ~12.3% ($6.72 → $12.02 est) — the EPS premium over revenue comes from margin expansion, buybacks, and Stericycle synergies, not unit acceleration.
Acceleration (the 2nd derivative) is negative: the FY25 ~14% revenue jump was the Stericycle acquisition, not organic; underlying core-price-led growth runs mid-single-digits and estimates show revenue growth easing from ~5% toward ~4% by FY30. Per our flagship philosophy we pick forward next-exponentials over trailing compounders — WM sits firmly at the mature-compounder end.
Room to run: the North-American waste market is enormous but largely already served by WM, Republic, and Waste Connections; WM is the share leader, so incremental TAM is thin. A 3× from here implies a ~$277B waste company — implausible without transformational M&A.
Reinvestment runway: real but modest — RNG plants, recycling automation, and bolt-on/adjacent M&A (Stericycle) extend the runway a few points, not a new curve.
Exponential Potential: Low (2/10). Own WM (if at all) for durable ~10–12% earnings compounding + a dividend + defensiveness, never for a fast multibagger. This is a bond-like equity, not a growth engine — the honest framing that keeps it out of any "next-exponential" sleeve.
Revenue: FY25 $25.20B, +14.2% (FY24 $22.06B, +8.0% on FY23 $20.43B). The FY25 step-up is largely the Stericycle/Healthcare Solutions acquisition; organic growth is mid-single-digit (core price +6.3%, volume slightly negative in Q1'26).
Quarterly trajectory: Q1'25 $6.02B → Q2 $6.43B → Q3 $6.44B → Q4 $6.31B → Q1'26 $6.23B (+3.5% YoY). Steady, not accelerating; Q1'26 volume dipped on harsh winter weather and intentional shedding of low-margin residential work.
Margins: gross 32% TTM, EBITDA margin ~29% (Q1'26 operating EBITDA margin 29.7%), net ~11% TTM. Best-in-class for the sector and expanding ~70 bps YoY on pricing and automation.
Earnings: net income $2.71B FY25; EPS $6.72 (diluted $6.70) vs FY24 $6.84 — reported EPS was flat/down YoY because Stericycle added interest expense and D&A and diluted near-term; adjusted EPS growth is the cleaner read. FY25 D&A jumped to ~$2.86B (was ~$2.4B) on the larger asset base.
Cash flow: operating CF $6.04B FY25 (+12%), capex −$3.23B (heavy: ~12% of revenue, funding fleet/RNG/recycling), FCF ~$2.82B (+30% YoY). Q1'26 FCF nearly doubled YoY to $920M — the clearest tell the growth-capex cycle is starting to convert.
Balance sheet: net debt ~$22.7B, net-debt/EBITDA ~3.1× (elevated post-Stericycle; management targets 2.5–3.0× and says it returned to range in Q1'26). Investment-grade, easily serviced (interest coverage ~5×), but leverage is the real risk line here, not solvency.
6. Valuation — priced in or room?
WM is not cheap on any trailing metric: 33× trailing EPS, 4.5× EV/sales, 15.6× EV/EBITDA, 9.3× book. The bull's defense is the forward curve: on live consensus, P/E compresses to 28× (FY26E) → 25× (FY27E) → 22× (FY28E) → 19× (FY30E) — i.e. the multiple works down meaningfully even at a flat price if estimates hit. But that math still requires paying ~25× forward for a ~5% revenue grower, which is a full price for the quality.
A reverse read: today's $230.40 against ~$8.18 FY26E EPS (28×) prices WM like a premium defensive compounder with reliable low-double-digit EPS growth — reasonable, but with no margin of safety if pricing power fades or recycling/RNG commodity prices stay soft. Street targets (context): consensus $258.50, high $264, low $250 — notably, the stock at $230 trades below even the Street's low target, which is the one genuine "the Street sees upside" data point in the file. Our base FV of ~$235 is deliberately more conservative than the Street because we discount the 28×+ forward multiple on mid-single-digit growth. Verdict: quality-at-a-full-price, hence Watch rather than Buy.
7. Technicals (from the tech block)
Trend: mildly up / range-bound. $230.40 sits just above the 50-DMA ($220.75) and 200-DMA ($221.47), with the two averages nearly on top of each other — a flat, consolidating tape, not a strong trend.
Location:−6.5% off the 52-week high ($246.51), +17% off the 52-week low ($196.77); max drawdown from peak only −6.5% — low-volatility, as befits beta 0.46.
Momentum: RSI(14) 68 — near the overbought line (70) after a bounce, so today's print is not a low-risk entry.
Relative strength (the tell): WM +0.7% 12-mo vs SPY +20.6% and QQQ +30.3%; −0.3% 3-mo vs SPY +13.7%. WM has badly lagged the market over the past year — classic defensive underperformance in a risk-on tape.
Read: technicals are neutral-to-cautious for a new entry — range-bound, RSI stretched, lagging the market. A pullback toward the ~$220 moving-average cluster (or lower) would be a materially better risk/reward than chasing at $230 with RSI 68.
8. Moat & competitive position
WM's moat is one of the widest in the industrials universe and rests on irreplaceable landfill assets: permitting a new landfill in North America is nearly impossible, so WM's continent-leading disposal network is a structural, appreciating asset that competitors must pay WM to use (internalization). Layered on top: route density (the more customers per truck-mile, the lower the cost — a scale flywheel), long-term municipal contracts, switching friction, and pricing power (core price +6.3% in Q1'26, ahead of cost inflation). This is a genuine wide-moat compounder; the debate is price, not quality.
Peer set (from file; market cap): the cleanest direct comps are Republic Services (RSG) $66.9B and Waste Connections (WCN) $42.9B — the other names in the FMP peer list (Cintas $72.6B, Emerson $77.9B, ITW $78.5B, Johnson Controls $85.9B, 3M $83.7B, Northrop $78.0B, TransDigm $75.4B, UPS $82.6B) are size-matched industrials, not business comps. Against RSG and WCN, WM is the scale leader with the largest landfill and collection network; all three trade at premium waste-sector multiples, and WM's is the richest — justified by its scale but leaving the least valuation room.
9. Management, capital allocation & guidance
Capital allocation: disciplined and shareholder-friendly — heavy productive capex (~$3.2B/yr into fleet, RNG, recycling automation), a growing dividend ($3.54/yr, ~1.5% yield, ~49% payout), and share repurchases ($344M in Q1'26). The big swing was the ~$7.5B Stericycle acquisition (2024), which pushed leverage up but added the Healthcare Solutions platform; management is now deleveraging back toward its 2.5–3.0× target (says it returned to range in Q1'26). Buybacks are secondary to reinvestment and deleveraging — appropriate at this leverage.
Insider activity: the sampled window (May–Jun 2026) is dominated by routine equity awards and option-exercise-plus-sale (e.g., SVP Carrasco exercised options at $126 and sold at $220 — mechanical, not a signal) and in-kind tax withholding. No cluster of alarming discretionary open-market selling.
Management's own guidance (half-weighted — their self-interested words): the SEC 8-K earnings release for Q1'26 (dated 2026-04-28) is a real earnings release and reads as one. Management reaffirmed its full-year 2026 financial outlook, citing Q1 adjusted operating EBITDA growth of 5.9% with 70 bps of margin expansion, core price of 6.3%, collection-and-disposal yield of 3.9%, and free cash flow that nearly doubled YoY ($920M vs $475M). CEO Jim Fish framed the start to 2026 as strengthening conviction in the recycling, RNG, medical-waste (Stericycle), and technology/automation investments. Treat as management's own book: it corroborates the steady-compounder thesis but is not independent confirmation.
10. Catalysts & what to watch
Next earnings: 2026-07-28 (Q2'26; Street EPS $2.01, revenue ~$6.69B). Key lines: core price vs cost spread, collection-and-disposal volume (was −1.5% in Q1 on weather/shedding — does it turn positive?), and Stericycle/Healthcare synergy capture.
Free-cash-flow conversion: continued FCF inflection as the growth-capex cycle (RNG plants, recycling automation) rolls toward harvest — the single best confirmation the reinvestment is paying.
Deleveraging: net-debt/EBITDA trending back into the 2.5–3.0× target range post-Stericycle.
Commodity/credit prices: recycled-commodity, RNG (natural gas), RIN/RFS-credit, and electricity prices — swing factors for the Recycling and Renewable Energy segments (recycled commodity ~$65/ton in Q1'26 vs ~$88 prior year — a headwind).
Volume trend: whether intentional low-margin shedding and weather effects give way to organic volume growth.
Thesis tripwires (what would change the call): core price decelerating below cost inflation; two quarters of margin compression; FCF conversion stalling; leverage failing to trend back toward target; or a de-rating that finally opens a genuine entry (which would flip this toward Buy).
11. Key risks
Valuation / no margin of safety (primary): 33× trailing / 28× forward for a ~5% revenue grower — a demand, pricing, or margin disappointment has little cushion and would de-rate the stock.
Leverage: net-debt/EBITDA ~3.1× post-Stericycle is elevated for the sector; a higher-for-longer rate path raises refinancing cost (interest expense already stepped up to ~$912M FY25).
Integration risk: Stericycle is a large, historically messy asset; synergy shortfalls or lingering integration costs would pressure the FY26 outlook.
Commodity exposure: recycling-commodity, RNG, and RIN/RFS-credit prices are volatile and were a YoY headwind in Q1'26 — the "growth overlay" segments cut both ways.
Volume cyclicality: industrial and construction volumes are economically sensitive; a hard recession dents the industrial/roll-off business even as the collection base stays sticky.
No expert corroboration: the Synthos KB has zero coverage — this call has less independent triangulation than a conviction-track name.
12. Verdict, position sizing & monitoring
Watch. WM is a genuinely elite, wide-moat, recession-proof compounder — 29% EBITDA margins, 29% ROE, irreplaceable landfill assets, pricing power, low beta, a growing dividend, and FCF that is inflecting as the capex cycle harvests. The single problem is price: at 33× trailing / 28× forward and 3.1× levered, the stock already pays for the quality, and it is a ~5% revenue grower with a decelerating profile and no Synthos expert conviction behind it. That combination is a Watch, not a Buy — a wonderful business we would happily own at a better price.
Sizing: if held, treat WM as defensive ballast (~2–4%) — a low-beta anchor and dividend compounder, not an alpha/satellite position. New money is better deployed on a pullback toward the ~$220 moving-average cluster or lower (our base FV is ~$235, only ~2% up).
Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. A de-rate toward ~22× forward, or an organic-volume/FCF acceleration, would flip this to Buy — Core. Logged as a tracked Synthos call as of 2026-07-03 at $230.40.
Single biggest risk: paying a premium growth multiple for a mid-single-digit-growth business — the price, not the business, is the reason to wait.
Provenance & disclosures
Traceability:0 KB claims, breadth 0 — there is no expert coverage of WM in the Synthos knowledge base, so this note carries noclaim_id citations. The verdict is explicitly fundamentals- and quant-driven; conviction is not asserted where it does not exist.
Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-03 · no expert claims. Forward figures are analyst consensus (FMP), labeled as estimates.
Management caveat: the Q1'26 8-K guidance (reaffirmed FY26 outlook) is management's own, half-weighted by design.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").